United Therapeutics Corporation $UTHR Stake Boosted by Focus Partners Advisor Solutions LLC

Focus Partners Advisor Solutions LLC increased its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 115.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,136 shares of the biotechnology company’s stock after purchasing an additional 2,220 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in United Therapeutics were worth $2,015,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Westerkirk Capital Inc. lifted its stake in United Therapeutics by 18.4% during the fourth quarter. Westerkirk Capital Inc. now owns 586 shares of the biotechnology company’s stock worth $286,000 after purchasing an additional 91 shares during the last quarter. Waddell & Associates LLC bought a new stake in United Therapeutics in the fourth quarter valued at $444,000. Fox Run Management L.L.C. bought a new stake in United Therapeutics in the fourth quarter valued at $1,280,000. Cerity Partners LLC lifted its stake in United Therapeutics by 134.3% in the fourth quarter. Cerity Partners LLC now owns 30,804 shares of the biotechnology company’s stock valued at $15,009,000 after buying an additional 17,657 shares during the last quarter. Finally, LPL Financial LLC lifted its stake in United Therapeutics by 3.1% in the fourth quarter. LPL Financial LLC now owns 10,186 shares of the biotechnology company’s stock valued at $4,963,000 after buying an additional 302 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Royal Bank Of Canada cut their target price on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Raymond James Financial assumed coverage on United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price on the stock. Bank of America raised their target price on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research note on Tuesday, March 31st. Finally, UBS Group raised their target price on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $619.42.

Insider Transactions at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 625,059 shares of company stock worth $352,648,188 over the last quarter. 8.60% of the stock is owned by insiders.

United Therapeutics Stock Down 1.6%

NASDAQ:UTHR opened at $544.10 on Thursday. The business’s 50-day moving average price is $568.19 and its 200 day moving average price is $520.67. The firm has a market cap of $23.10 billion, a P/E ratio of 20.08, a PEG ratio of 1.80 and a beta of 0.57. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm earned $6.63 earnings per share. Sell-side analysts expect that United Therapeutics Corporation will post 26.84 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.